Global Online Gambling Market Size, Industry Trends, Share and Forecast 2019-2025
The global online gambling industry is estimated to register lucrative growth over the forecast period 2019-2025. Factors that augment the business growth of the market include high internet penetration coupled with the increasing use of mobile phones. Moreover, ease of access to online gambling, legalization & cultural approval, corporate sponsorships, and celebrity endorsements are further fueling the growth of the market. Apart from this, the growing availability of cost-effective online gambling mobile applications across the globe is also driving the market growth. The recent COVID-10 outbreak, which prompted several governments to prohibit social gatherings and announce full lockdown, has impacted a segmental performance of the industry. Request a Free Sample of our Global Online Gambling Market:https://www.omrglobal.com/request-sample/online-gambling-market The report analyzes the global online gambling market on the basis of type and geography. Based on the type, the market is segmented into sports betting, casinos, poker, and bingo.Sports betting contributes significant revenue to the global online gambling industry; however, it has been hit hard by the spread of the deadliest virus across the globe. Several sports events and tournaments including Indian Premier League (IPL) 13, UEFA Euro Cup 2020, Summer Olympics 2020 have been either postponed or canceled, providing a heavy blow to the several online sports betting companies. Further, amid the virus crisis and no sports tournaments or events in place, bettors are shifting to other gambling types such as pokers and casinos. Thereby, fueling the other segmental growth of the market. A full Report of Global Online Gambling Market is Available at:https://www.omrglobal.com/industry-reports/online-gambling-market The global online gambling market is analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. The market has been segmented into North America, Europe, Asia Pacific and Rest of the World (RoW). Europe is expected to be the major region in the global online gambling market owing to the legalization of gambling in countries such as France, Germany, Spain, and Italy. Moreover, other factors that fuel the regional business growth include the significant presence of major players, such as William Hill PLC, Cherry AB, 888 Holdings PLC, and several others in the region; and high penetration of the internet coupled with the high smartphone penetration across the region. Asia-Pacific is estimated to be the fastest-growing region in the global online gambling market due to the growing use of internet services and the relaxation of regulations pertaining to online betting & gambling. Global Online Gambling Market Segmentation · Type · Sports Betting · Casinos · Poker · Bingo Regional Analysis · North America · United States · Canada · Europe · UK · Germany · Italy · Spain · France · Rest of Europe · Asia-Pacific · China · India · Japan · Rest of Asia-Pacific · Rest of the World Companies Studied · 888 Holdings PLC · Bet365 Group Ltd. · Betsson AB · Cherry AB · GVC Holdings PLC · Kindred Group PLC · Ladbrokes Coral Group PLC · Flutter Entertainment PLC · The Stars Group Inc. · William Hill PLC For More Customized Data, Request for Report Customization @https://www.omrglobal.com/report-customization/online-gambling-market About Orion Market Research Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. For More Information, VisitOrion Market Research Media Contact: Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: [[email protected]](mailto:[email protected]) Contact no: +91 7803040404
Global An Gambling Market Outlook 2023 Growth by Top Company, Shares, Size, Trends and Challenges with Forecast to 2023
Global An Gambling Market Research Report presents point by point data on the current market trends, future advancement extension and industry growth is displayed. The business techniques connected for An Gambling development are clarified. Every single significant component like market share, An Gambling geographical regions, market drivers, CAGR esteem and market factors are assessed. The focused situation between An Gambling industry, key drivers are considered. Global top sellers, manufacturer's of An Gambling Market, production capacity, development rate, utilization and import-export subtleties are clarified. Top topographical districts dissected in the examination include North America, Europe, Asia-Pacific, Middle East and Africa and South America. The An Gambling product presentation, varied applications, types are clarified in this examination. Download Free Sample Report Copy @:https://www.globalmarketers.biz/report/technology-and-media/global-an-gambling-industry-market-research-report/3653#request_sample Global An Gambling Market Segment by Manufacturers, this report covers: Major Players in An Gambling market are: Casino de Monte Carlo Expekt.com The Casino at the Empire Betsson Group Betclic Casino Estoril Casino di Campione ZEAL Bet-at-home.com Resorts World Birmingham Global An Gambling Market Segment by Type, covers Slot Machines Roulette Poker Lottery Scratchcards Blackjack Bingo Others Global An Gambling Market Segment by Applications can be divided into: Non-Gamblers Light-Medium Gamblers Heavy Gamblers Imperative data on development opportunities, market hazards in An Gambling industry will delineate the business execution at present and in not so distant future. An Gambling Industry plans and approaches, new product launch events, mergers and securing and innovative headways are clarified. The upstream raw material providers of An Gambling, manufacturing base, cost structures and production process examination are broke down. Likewise, the marketing channels of An Gambling industry, downstream purchasers, work cost included and value structures are expounded. The Global An Gambling market value and growth rate for each application, type and region is studied from 2013-2018. The import-export details, production and consumption status of An Gambling Market is provided for every region and key countries present in this region. Furthermore, the SWOT analysis to predict the An Gambling growth drivers, threats to the industry are studied. Segment An Gambling competitive landscape will illustrate the dynamic competitive scenario among elite players in this market. A complete product portfolio, market share in 2017, and gross margin status is covered. In the next part, market value, volume and An Gambling consumption forecast from 2018-2023 are conducted. The forecast analysis will help in strategic business planning to achieve substantial growth in future. This will also lead to new project plans and investment feasibility analysis. Inquire Here For More Information @:https://www.globalmarketers.biz/report/technology-and-media/global-an-gambling-industry-market-research-report/3653#inquiry_before_buying The An Gambling report projects advancements and futuristic demand from 2018-2023. Downstream demand, raw materials analysis and market dynamics are explained. An extensive and valuable analysis with the latest development will provide feasibility study. All significant An Gambling parameters and complete insights on industry facts are explained. The revenue, capacity, manufacturing, production rate and import-export status are presented. Lastly, research conclusions, data sources, in-depth research methodology and analysts view, suggestions are offered. Key Features Of Global An Gambling Market Report Are As Follows: The assessment of growth opportunities in An Gambling with market size, share and forecast data is covered in this report. The growth drivers of this industry are extensively focused. Top elite An Gambling industry players, their business plans and tactics are explained with the analysis of market risks. Revenue analysis, market status, production and consumption analysis is presented. The segmented An Gambling industry analysis provides a key focus on every segment like product types, applications and geographical regions. The study of past market status, the present status will lead to forecast study and market share view. An in-depth study on company profiles, product portfolio, sales, revenue and gross margin statistics is conducted. Additional players can be studied as per the user’s interest. Browse Table Of content @:https://www.globalmarketers.biz/report/technology-and-media/global-an-gambling-industry-market-research-report/3653#table_of_contents An Gambling analysis of upstream buyers, industry chain view, manufacturing process and downstream suppliers will provide useful industry insights. Financial analysis and key advancements to be taken place in the near future are portrayed in this study. Consumption, production and revenue forecast are key attractions of the report. Also, the information on traders, distributors, manufacturers and dealers are covered on a global scale. Contact us: Global Marketers Tel: +1-617-2752-538 Email:[[email protected]](mailto:[email protected]) Visit Our Blog:http://industrynewsdesk.com
Global Women Intimate Care Market: Technology, Future Trends, Market Opportunities 2019 & Key Players: Procter & Gamble, Himalaya Drug, Unicharm, etc.
Women Intimate Care Market The Global Women Intimate Care Market Report Forecast 2019-2024 is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. This Market study provides comprehensive data which enhances the understanding, scope, and application of this report. Top Companies in the Global Women Intimate Care Market: Procter & Gamble, Himalaya Drug, Unicharm, Kimberly-Clark, Elif Cosmetics, Nlken Hygiene Products, Johnson & Johnson Services, Ciaga, Zeta Farmaceutici, Edgewell Personal Care, Emilia Personal Care, Nua Woman, Kao Corporation, Bodywiseuk and more. Click the link to get a Sample Copy of the Report:https://www.acquiremarketresearch.com/sample-request/167830/ The research report on the Global Women Intimate Care market includes a SWOT analysis and Porter’s five forces analysis, which help in providing the precise trajectory of the market. These market measurement tools help in identifying drivers, restraints, weaknesses, Women Intimate Care market opportunities, and threats. The research report offers global market figures as well as figures for regional markets and segments therein. Global Women Intimate Care Market Split By product type And Applications: This report segments the global Women Intimate Care Market on the basis of Types are: Intimate Wash, Masks, Moisturizers and Creams, Hair Remova. On the basis of Application, the Global Women Intimate Care Market is segmented into Online Retailers, Hypermarket, Specialty Store. Global Women Intimate Care Market by Regions:North America (United States, Canada, and Mexico) Europe (Germany, France, UK, Russia, and Italy) Asia-Pacific (China, Japan, Korea, India, and Southeast Asia) South America (Brazil, Argentina, Colombia) Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa) Enquire Before Purchasing This Report @https://www.acquiremarketresearch.com/enquire-before/167830/ Influence of the Women Intimate Care Market report: -Comprehensive assessment of all opportunities and risk in the Women Intimate Care Market. – Women Intimate Care Market recent innovations and major events. - A Detailed study of business strategies for the growth of the Women Intimate Care Market-leading players. -Conclusive study about the growth plot of Women Intimate Care Market for forthcoming years. -In-depth understanding of Women Intimate Care Market-particular drivers, constraints and major micro markets. -Favorable impression inside vital technological and market latest trends striking the Women Intimate Care Market. Click the link to Purchase This Full Report @https://www.acquiremarketresearch.com/industry-reports/women-intimate-care-market/167830/ What are the market factors that are explained in the report? -Key Strategic Developments: The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale. -Key Market Features: The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments. –Analytical Tools: The Global Women Intimate Care Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porter’s five forces analysis, feasibility study, and investment return analysis have been used to analyzed the growth of the key players operating in the market. Finally, Women Intimate Care Market report is the believable source for gaining the Market research that will exponentially accelerate your business. The report gives the principle locale, economic situations with the item value, benefit, limit, generation, supply, request and Market development rate and figure and so on. This report additionally Present new task SWOT examination, speculation attainability investigation, and venture return investigation.
Global Mascara Market: Technology, Future Trends, Market Opportunities 2019 & Key Players: LOreal, Estee Lauder, Procter & Gamble, LVMH, etc.
https://preview.redd.it/vevhmuujm6d31.jpg?width=700&format=pjpg&auto=webp&s=0293f5b597704e08a86f554d1b52eaf091ddea74 Mascara market research delivers real-world and industry intelligence of the market to support your idea with research-based facts. It provides deep understanding, clarifies diversities of the market to help you decide not only the succeeding strategy but also to achieve the desired market position in Power sector. This market research is a combined result of inputs from business professionals with awareness, the experience of Mascara industry and qualitative and quantitative synthesis of the market. Request for Sample Report Here @https://www.acquiremarketresearch.com/sample-request/13358/ This report presents a detailed study of the global market for Mascara by evaluating the growth drivers, restraining factors, and opportunities at length. The examination of the prominent trends, driving forces, and the challenges assist the market participants and stakeholders to understand the issues they will have to face while operating in the worldwide market for Mascara in the long run. This report provides in depth study of “Mascara” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Mascara report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling, the product outline, the quantity of production, required raw material, and the financial health of the organization. For More Information On This Report, Please Visit @https://www.acquiremarketresearch.com/industry-reports/mascara-market/13358/ It further maps the competitive landscape of this Mascara market by evaluating the company profiles of the leading market players, such as LOreal, Estee Lauder, Procter & Gamble, LVMH, Coty, Avon, Shiseido, Amore Pacific, Missha, Chanel, Mary Kay, Alticor, PIAS, Natura, Revlon, Oriflame, Groupe Rocher, Kose Corp, Beiersdorf, DHC, Thefaceshop, Gurwitch, Pola Orbis, Marie Dalgar, Elizabeth Arden On the basis of the product, the market has been classified into: Regular, Waterproof, Water Resistant Based on the application, the market has been categorized into: Daliy use, Performing use Any query?Inquire Here For Discount Or Report Customization (Use Corporate email ID to Get Higher Priority):https://www.acquiremarketresearch.com/enquire-before/13358/ Global Mascara Report mainly covers the following Chapters: => Chapter 1: Mascara Industry Overview. => Chapter 2: Mascara Region and Country Market Analysis. => Chapter 3: Mascara Technical Data and Manufacturing Plants Analysis. => Chapter 4: Mascara Production by Regions by Technology by Applications. => Chapter 5: Mascara Manufacturing Process and Cost Structure. => Chapter 6: Mascara Productions Supply Sales Demand Market Status and Forecast. => Chapter 7: Mascara Key success factors and Market Overview. => Chapter 8: Mascara Research Methodology and About Us. Please note Chapters four, five and six data will depend on the feasibility of the Mascara market.
The #1 online casino company $RSI is primed for autism
Positions: $RSI 30 03/19 30C Proof: https://imgur.com/a/swCCMjz *This post is for informational purposes only, you should not construe any such information or other material as investment, financial, or other advice.* TLDR: Rush Street Interactive ($RSI) is the #1 nationwide online casino company and the #3 or #4 sports book depending on the state. Short selling, unwarranted institutional wariness of share dilution and the general market focus on sports book instead of online casino has left $RSI grossly undervalued. A massive blow out at Q4 earnings will result in analyst upgrades and a rapid repricing by market makers and institutions seeking exposure to the emerging sector. **Overview** "Sports book is really just kind of a warm up in a lot of ways for an online casino where the real money is made" - Niccolo De Masi, CEO dMY technologies Rush Street Interactive ($RSI) operates the BetRivers.com online casino and sports book. They are now fully licensed and operating in New Jersey, Pennsylvania, Michigan, Illinois, Indiana, Colorado, Iowa, and Virginia. They own and operate a casino in New York and already have a New York license making them well positioned for liberalization there. They merged with a dMY Technology Group SPAC on Dec. 31st 2020 with 240 million on the balance sheet to spend on growth. The online casino business is fundamentally more profitable than sports betting because the average value of a casino player is estimated at $600 while a sports book player could be as little as $20. Estimates put the online casino market at DOUBLE the size of the online sports book market and the online casino industry is really just getting started as more states liberalize. $RSI is expert at new market entry; they have been first to market in Pennsylvania, Illinois, Indiana, and Colorado and even when they aren't first they are capable of capturing market share in competitive markets such as New Jersey. They also have products which women play which accounts for at least half of the market in online casino. The female market is one that the pure sports book plays miss out on. Also for some fucking reason they operate a casino and sports book in Colombia (rushbet.co) and may make large expansions into other parts of south America as legalization continues. This means they have the expertise necessary for global expansion in the future although the states remains their primary focus and growth driver. **The Financials and Strategy** Unlike other companies in the space Rush Street is already profitable in 2020 and has a strong focus on Return On Invested Capital (ROIC). Q3 gross revenue was $71.9 Million. Q4 revenue is going to be a blow out. Combing through state gambling revenue data and breaking that down by market share my estimate is that Q4 revenue could be as high as $120 Million. Paired with this blow out will be a **guidance raise to $500 Million for 2021**, which is 2/3 of DraftKings 2021 guidance of $750M. https://imgur.com/a/xkfcayC What is striking when compared to $DKNG is that their advertising spend was only a quarter of revenue in Q3 while $DKNG spent 155% of their revenue. This will change as they begin to focus on growth, but it shows they are very good at getting return on ad spend. This company should actually be valued close to $DKNG based on growth potential once guidance is raised. https://imgur.com/a/RQQXtGg Their focus on attracting **female gamers** is also important to their long term growth potential. The sports book plays with cross sells to casino such as $DKNG will not be able to grow through the female demographic in the same way. **This cannot be understated** as one of the major strategic advantages of $RSI. https://imgur.com/a/xzJj26n As I said before I expect their trend of rapid growth to continue for Q4 earnings, certainly going to be a blow out based on looking at state gambling revenue numbers. My estimate is that their revenue will be around 110M for Q4. I also expect guidance to be raised to 500M for 2021 due to strong performance in existing markets and the recently opened Michigan market as well as their sports book launch in Virginia. https://imgur.com/a/ckTqHhh **Short sellers have entered the chat** The short interest on $RSI sits at 5.08 M shares as of 01/14/21 representing a 30% increase. Now why would a company already valued at 2.8 Billion and with a comparative valuation of 8-10 Billion compared with $DKNG and $PENN be so heavily shorted at such a low market cap? My conclusion is that an institution with 10s of millions to throw at shorting this stock wants to take advantage of fear of share dilution from warrant calling or to establish a better entry prior to earnings. **Commander in GILF Cathie Wood is Bullish on the sector** On Feb. 2nd ARK disclosed that they had purchased 620,300 shares of $DKNG. This is extremely bullish for the sector. I am highly confident that after Q4 earnings ARK will be purchasing shares in $RSI as well due its strategic advantages relative to $DKNG and exposure to the female demographic. For such a small market cap company this will be a major catalyst. **Institutions are bullish** Fidelity has increased their holdings to 14% as of today: https://d18rn0p25nwr6d.cloudfront.net/CIK-0001793659/8f10b0d8-a3d2-447c-bc75-87587d0a4670.pdf Alliance Bernstein holds a 6% position reported today: http://d18rn0p25nwr6d.cloudfront.net/CIK-0001793659/e883778d-e759-4a85-91c1-3242ed110720.pdf **Final notes** Jerome "The Bus" Bettis, Steelers legend and hall of fame running back, is their brand ambassador... This company knows their target audience and how to appeal to them, likely more 'classic' ambassadors to come to attract even more boomer and Gen X degenerates. Keep in mind these are the gamblers with big money to spend, the average age of an online casino gambler is 42. This stock has been grossly underpriced due to short selling. The terms of the SPAC deal were not unfavorable and all the insiders held their shares through the merger banking on growth in the market - **management owns 77% of the company**. This is a true value play on a well managed company in an emerging industry with a market size in the hundreds of billions. I plan to hold shares long term. I will post a part 2 breaking down their latest S-1 filing and Q4 revenue by state when they release their Q4 earnings date. Do your own research. References: https://www.legalsportsreport.com/sports-betting/revenue/ https://fintel.io/doc/sec-rush-street-interactive-inc-ex991-2021-january-05-18632-947 https://s26.q4cdn.com/794539746/files/doc_presentations/2020/RSI-Investor-Presentation-15-Oct-2020.pdf https://ir.rushstreetinteractive.com/news/news-details/2020/RUSH-STREET-INTERACTIVE-ANNOUNCES-THIRD-QUARTER-2020-RESULTS-AND-RAISES-FULL-YEAR-GUIDANCE/default.aspx https://www.youtube.com/watch?v=SQWEhWuPmzU https://www.thestreet.com/investing/draftkings-surges-as-stake-bought-by-ark-next-generation Positions: $RSI 30 03/19 30C I will be adding 04/16 25cs each week until earnings. Exit strategy: "What's an exit strategy?" - u/deepfuckingvalue Update 021321: IMPORTANT after a commenter pointed out that technically they could report as late as April 2nd I AM RECOMMENDING THAT EVERYONE ROLL OUT TO APRIL 16TH 35Cs
The #1 online casino company $RSI is primed for ingress.
Positions: $RSI 03/19 30C Proof: https://imgur.com/a/swCCMjz This post is for informational purposes only, you should not construe any such information or other material as investment, financial, or other advice. TLDR: Rush Street Interactive ($RSI) is the #1 nationwide online casino company and the #3 or #4 sports book depending on the state. Short selling, unwarranted institutional wariness of share dilution and the general market focus on sports book instead of online casino has left $RSI grossly undervalued. A massive blow out at Q4 earnings will result in analyst upgrades and a rapid repricing by market makers and institutions seeking exposure to the emerging sector. Overview "Sports book is really just kind of a warm up in a lot of ways for an online casino where the real money is made" - Niccolo De Masi, CEO dMY technologies Rush Street Interactive ($RSI) operates the BetRivers.com online casino and sports book. They are now fully licensed and operating in New Jersey, Pennsylvania, Michigan, Illinois, Indiana, Colorado, Iowa, and Virginia. They own and operate a casino in New York and already have a New York license making them well positioned for liberalization there. They merged with a dMY Technology Group SPAC on Dec. 31st 2020 with 240 million on the balance sheet to spend on growth. The online casino business is fundamentally more profitable than sports betting because the average value of a casino player is estimated at $600 while a sports book player could be as little as $20. Estimates put the online casino market at DOUBLE the size of the online sports book market and the online casino industry is really just getting started as more states liberalize. $RSI is expert at new market entry; they have been first to market in Pennsylvania, Illinois, Indiana, and Colorado and even when they aren't first they are capable of capturing market share in competitive markets such as New Jersey. They also have products which women play which accounts for at least half of the market in online casino. The female market is one that the pure sports book plays miss out on. Also for some fucking reason they operate a casino and sports book in Colombia (rushbet.co) and may make large expansions into other parts of south America as legalization continues. This means they have the expertise necessary for global expansion in the future although the states remains their primary focus and growth driver. The Financials and Strategy Unlike other companies in the space Rush Street is already profitable in 2020 and has a strong focus on Return On Invested Capital (ROIC). Q3 gross revenue was $71.9 Million. Q4 revenue is going to be a blow out. Combing through state gambling revenue data and breaking that down by market share my estimate is that Q4 revenue could be as high as $120 Million. Paired with this blow out will be a **guidance raise to $500 Million for 2021**, which is 2/3 of DraftKings 2021 guidance of $750M. https://imgur.com/a/xkfcayC What is striking when compared to $DKNG is that their advertising spend was only a quarter of revenue in Q3 while $DKNG spent 155% of their revenue. This will change as they begin to focus on growth, but it shows they are very good at getting return on ad spend. This company should actually be valued close to $DKNG based on growth potential once guidance is raised. https://imgur.com/a/RQQXtGg Their focus on attracting **female gamers** is also important to their long term growth potential. The sports book plays with cross sells to casino such as $DKNG will not be able to grow through the female demographic in the same way. **This cannot be understated** as one of the major strategic advantages of $RSI. https://imgur.com/a/xzJj26n As I said before I expect their trend of rapid growth to continue for Q4 earnings, certainly going to be a blow out based on looking at state gambling revenue numbers. My estimate is that their revenue will be around 110M for Q4. I also expect guidance to be raised to 500M for 2021 due to strong performance in existing markets and the recently opened Michigan market as well as their sports book launch in Virginia. https://imgur.com/a/ckTqHhh Short sellers have entered the chat The short interest on $RSI sits at 5.08 M shares as of 01/14/21 representing a 30% increase. Now why would a company already valued at 2.8 Billion and with a comparative valuation of 8-10 Billion compared with $DKNG and $PENN be so heavily shorted at such a low market cap? My conclusion is that an institution with 10s of millions to throw at shorting this stock wants to take advantage of fear of share dilution from warrant calling or to establish a better entry prior to earnings. Cathie Wood is Bullish on the sector On Feb. 2nd ARK disclosed that they had purchased 620,300 shares of $DKNG. This is extremely bullish for the sector. I am highly confident that after Q4 earnings ARK will be purchasing shares in $RSI as well due its strategic advantages relative to $DKNG and exposure to the female demographic. For such a small market cap company this will be a major catalyst. Final notes Jerome "The Bus" Bettis, Steelers legend and hall of fame running back, is their brand ambassador... This company knows their target audience and how to appeal to them, likely more 'classic' ambassadors to come to attract even more boomer and Gen X degenerates. Keep in mind these are the gamblers with big money to spend, the average age of an online casino gambler is 42. This stock has been grossly underpriced due to short selling. The terms of the SPAC deal were not unfavorable and all the insiders held their shares through the merger banking on growth in the market - **management owns 77% of the company**. This is a true value play on a well managed company in an emerging industry with a market size in the hundreds of billions. I plan to hold shares long term. I will post a part 2 breaking down their latest S-1 filing and Q4 revenue by state when they release their Q4 earnings date. Do your own research. References: https://www.legalsportsreport.com/sports-betting/revenue/ https://fintel.io/doc/sec-rush-street-interactive-inc-ex991-2021-january-05-18632-947 https://s26.q4cdn.com/794539746/files/doc_presentations/2020/RSI-Investor-Presentation-15-Oct-2020.pdf https://ir.rushstreetinteractive.com/news/news-details/2020/RUSH-STREET-INTERACTIVE-ANNOUNCES-THIRD-QUARTER-2020-RESULTS-AND-RAISES-FULL-YEAR-GUIDANCE/default.aspx https://www.youtube.com/watch?v=SQWEhWuPmzU https://www.thestreet.com/investing/draftkings-surges-as-stake-bought-by-ark-next-generation Positions: $RSI 03/19 30C I will be adding 04/16 25Cs each week until earnings Exit strategy: "What's an exit strategy?" - u/deepfuckingvalue Forgot to add: http://d18rn0p25nwr6d.cloudfront.net/CIK-0001793659/8f10b0d8-a3d2-447c-bc75-87587d0a4670.pdf Fidelity just doubled their position to almost 15% Update 021221: Everyone that went in on my initial entry is down 40% right now. As I said I plan to continue to buy 03/19 25Cs each week until earnings. If you’re worried about further losses wait until the day before earnings to load up, you may miss a run up though. Update 021321: IMPORTANT after a commenter pointed out that technically they could report as late as April 2nd I AM RECOMMENDING THAT EVERYONE ROLL OUT TO APRIL 16TH 35Cs
Megathread: President Donald Trump announces he has tested positive for Coronavirus | Part II
President Donald Trump announced he and First Lady Melania Trump had tested positive for the virus and will begin their quarantine and recovery process immediately. The news comes after it was announced that close presidential aide Hope Hicks tested positive Wednesday evening. Megathread Part I
The cannabis market right now is so similar to the start of the green energy market.. its nowhere near done being bullish. Save for some small dips, there will very likely be a huge bullish trend for 2021. EVEN NASDAQ AGREES. I’ve posted my positions a few times, and I’ll continue to do so. But this is my reasoning for investing in cannabis stocks in general for 2021.
I've been a bull on cannabis since the democrats had a strong pro-cannabis platform. But what made me go balls deep into the market was that the UN changed its classification of cannabis. Countries follow the UN closely for guidance on their own classification of controlled substances. Congress has repeatedly cited the UN’s classification as one of the reasons for not changing it. Several countries immediately changed their stance on cannabis in response to this, including Israel, which In November 2020, announced that it was moving forward with a plan to legalize recreational cannabis nationally. “The country is aiming to implement recreational legalization within nine months, and even if there are delays, that means mid-to-late 2021.” (This is my reason for investing in Canadian cannabis companies, because they are already poised to expand internationally since its legal there nationwide)
THE SENATE IS NOW BLUE! The Georgia runoffs were won by Democrats, and they can now swing the vote left with VP Harris. She promised it as part of her platform, so we know it will be prioritized. CHUCK SHUMER SPONSORED THE MORE ACT. HE WILL BE SENATE MAJORITY LEADER. IT WILL 100% BE PRIORITIZED BETWEEN HIM AND VP HARRIS.
EVERYONE predicted beforehand that the republicans would win Georgia... everyone talked down decriminalization passing the house because of they believed it would NEVER pass the republican majority senate. But the left spent more than any senate race in history to encourage voters to go out and vote. Only once the race started did it become clear that the left had a chance. Then some gains from the surprise that they won. However the gains from 1/5 onwards definitely hasn’t been priced in for all the future legislation, because some of it will be completely new legislation that wasn’t possible to consider before without a blue senate. THIS HASN'T BEEN PRICED INTO THE MARKET YET.
The government is broke post-COVID. There is a terrible image of the police. They don’t want to waste more resources on cannabis related crimes that would be fixed under decriminalization. And the tax revenue from decriminalization would be significant. Decriminalization (THE MORE ACT) opens up the borders to interstate-commerce and international import/export. This would all trickle down into Uncle Sam’s empty pockets.
New York Governor Cuomo announced on Jan 6 his plan to legalize marijuana for adult use (right after New Jersey vote, as I anticipated in my last post) as part of his State of the State agenda. The next step is a ripple out on the North East. NY didn’t want to miss out on tax revenue, neither will any of the other states in the northeast within driving distance of NJ and NY. This is Cuomo’s third attempt in three years to legalize adult-use cannabis in the state; last year, Cuomo included a legalization proposal in his state budget, but the plan was ultimately cut in the wake of the COVID-19 pandemic.
Other ongoing state legislature:
Rhode Island: Regulators have received 45 applications for six new medical cannabis dispensary licenses in the state. If all applicants meet the requirements for a license, six will randomly be selected in a lottery to operate retail locations in different regions across the state. Read more
Missouri: Rep. Shamed Dogan has filed legislation that would place an adult-use cannabis legalization measure on the state’s 2022 ballot. Meanwhile, Missourians for a New Approach has announced plans for a separate 2022 ballot initiative after an unsuccessful signature campaign to get the issue before voters in 2020. Read more
Alabama: Sen. Tim Melson plans to reintroduce a medical cannabis legalization bill this year. Medical cannabis legislation passed the Alabama Senate during the 2020 session, but failed to clear the House. Read more
Illinois: Illinois lawmakers have proposed the creation of 75 new cannabis retail licenses to give disadvantaged and minority applicants a second chance at licensing following the controversial licensing lottery to issue an initial 75 dispensary licenses. A work group made up of lawmakers and members of Gov. J.B. Pritzker’s administration met this week to finalize details of the bill, which will be introduced in a lame-duck session that starts Jan. 8, before new lawmakers are sworn in Jan. 13. Read more
Minnesota: House Majority Leader Ryan Winkler is again renewing his push to legalize adult-use cannabis in the state, announcing plans to reintroduce a legalization bill this year. Winkler told WCCO that he sees “Senate leadership as being the number one obstacle,” but said that if lawmakers agreed to place an adult-use legalization initiative on Minnesota’s 2022 ballot, “it would pass overwhelmingly.” Read more
Virginia: Del. Steve Heretick has reintroduced a bill to legalize adult-use cannabis. Heretick has proposed legislation related to decriminalization and legalization in the past, and this year’s bill would legalize the cultivation, sale and consumption of cannabis in the state. Read more
Connecticut: Gov. Ned Lamont renewed his push for adult-use legalization during his State of the State address Jan. 6, announcing that it is a priority for the new legislative session. Connecticut’s 2021 legislative session opened Jan. 6, and Lamont, a Democrat, kicks off the session with increased majorities in the House and Senate, which could increase his chances of passing an adult-use legalization bill. Read more
Now that you understand why I’m going green, here’s my reasoning for my positions. TLRY (Tilray)
largest cannabis company in the world by revenue post merger. Will run out of Seattle and New York City. New York Legalization on top of senate turning blue is a big catalyst for TLRY.
Merger hasn’t completed yet, and the merger happened before the senate went blue.. that was the gamble APHA was making, and they won. The sky is the limit now. When they merge, they will reduce expenses and be much more likely to post profitable quarters. (This is why mergers have so much hype; the sum is > than their parts because they can reduce operating expenses while maintaining revenue from the two companies)
Tilray CEO Brendan Kennedy: “I think medical cannabis will be legal at the federal level, which means medical cannabis can cross state lines and be imported into the U.S., like we export cannabis from Canada and Portugal to about 15 countries now,” Kennedy said. “Anyone who thinks there’s a state-specific medical market is wrong.” As for the recreational market, Kennedy says the state-specific markets, with interstate trade banned, “are not going to last long.” Kennedy believes that cannabis will be distributed like alcohol and tobacco within two years’ time. That would require significant overhaul of US federal drug laws—and would significantly disrupt all US cannabis companies’ existing business models. Brendan Kennedy, the cannabis billionaire will step down as Tilray's chairman and CEO. Irwin D. Simon, Aphria's current chairman and CEO will take Kennedy's place.
[On December 18, 2020, just three days after the U.S. Senate adopted the Cannabidiol and Marihuana Research Expansion Act (CMREA or the Act) (more on this below), the U.S. Drug Enforcement Administration (DEA or the Administration) published in the Federal Register a final rule, “Controls To Enhance the Cultivation of Marihuana for Research in the United States” (Rule), which finally paves the way for DEA to issue additional licenses to grow “marihuana” (i.e., cannabis) for research purposes.](https://www.jdsupra.com/legalnews/on-heels-of-senate-s-adoption-of-36129/)
GNLN (Greenlane Holdings)
One of the largest global sellers of premium cannabis accessories. Pax/JUUL/Volcano products. I’ve had Pax products, and although I prefer Arizer because of the affordability, I can’t deny Pax has quality products and is like the “iPhone” of vaporizers. I like their products, I like their branding. There’s lots of hype and loyalty, especially with their Volcano desktop vaporizer.
Strong US brands.
The main reason they did poorly was bad timing. They IPO’d during the year that JUULs started being banned. They’re actually at all those levels again. Theres a ton of upside potential.
Market cap is ridiculously low for some really renown brands all because of the JUUL flavor pod ban. Everyone knows Pax, Volcano, and JUUL. But no one knows Greenlane because of the bad timing of their IPO and the subsequent JUUL flavor ban. It’s crazy. They’ve already broke all time high for the year. But I’m holding until they break 1B market cap.
Overall i think too many people count it out just because of their IPO and subsequent decline in JUUL sales from the JUUL flavored pods ban. They definitely have the potential because of their strong branding and quality products. I’m betting on them having more high quality products in the future with equally loyal customers.
SNDL (Sundial Growers)
SNDL must close above $1 per share for 10 consecutive sessions by June 26, 2021 or it will bedelisted from NASDAQ. People see this as a fear factor, I see this as “they will do anything necessary to reach $1 for a week so they won’t be delisted”.. IMHO reverse splitter probably isn’t on the table since they could have done that in 2020, but instead applied for a 6 month extension after announcing “alternative strategic investments”. We can already see this by their predatory loan SPAC spinoff.
Rumors of a merger with CGC; SNDL also purchased a SPAC recently and entered an agreement with Zenabis, immediately claiming they defaulted. Turning that SPAC into predatory loan/debt repurchasing company. Imo if they want to complete a merger, it would be easy to sell ownership through that SPAC to the buyer.
THEY RECENTLY WENTDEBT FREE by selling off unprofitable assets in the business. This means we are much more likely to see earnings in future quarters, and they are much more attractive for mergers.
Because they are indoor growers, they are more likely to be bought up by a company in the consolidating Canadian cannabis market than fail all together. The amount of space licensed to grow cannabis in Canada is now heavily skewed toward outdoor cultivation instead of indoor for the first time, according to new data from Health Canada. A growing population of licenses for outdoor growers means that there aren’t as many indoor licenses being given out... If a company ANYWHERE IN THE WORLD wants to quickly expand into indoor growing OR into the west, they would have to purchase an existing company that has the license to quickly do so. This is WAY faster, and a guaranteed way to obtain a license rather than applying for one and waiting x amount of months and be rejected for some requirement that wasn’t met.
From my own experience, outdoor cannabis is subpar quality to indoor grown cannabis. So a growing market for outdoor cannabis doesn’t necessarily mean its better... it is likely just cheaper. I would imagine a high quality “craft cannabis” company would want to purchase SNDL, or an existing outdoor growing company that wants to quickly expand to indoor grown cannabis. With this being a Canadian company, there’s a chance a company in another country like Israel would be interested in purchasing it in the near future.
PLNHF (Planet 13 Holdings)
Biggest tourist trap in Las Vegas if you’re a stoner, casual smoker, or just wanting to try it. From my own experience, I think they will continue to be successful. If I went around the US trying other brands I’d probably be more confident in putting 5-10% of my portfolio into those picks or choosing to not include them lol. Like for example, I used to have Curaleaf. But there's tons of bad feedback on Curaleaf, a friend has tried it said the nug is really subpar quality and if I tried their nug I’d probably confirm that I wouldn’t want to invest in them. With PLNHF, i’ve seen the ambience and tried the product myself. It’s definitely a lot of hype price wise, but still quality. This is my own bias showing, but I still think they’ve got solid fundamentals and excellent location/strong US branding.
I’m well aware of other good stocks like GTBIF, CRLBF, SSPK, TCNNF, GRWG.. but these stocks haven’t been swinging as hard in response to pro-cannabis news. E.g. TLRY, SNDL, GNLN swung more than 20% some days from pro-cannabis news...I will likely reduce my current positions shortly after inauguration, after some news about the timeline for cannabis legislation, and diversify my positions more between these other good picks. 2021 is the year of cannabis boys
@TraceSafeTech and Why We Love it - written by @mrdotto5 @stockfamgroup $TSF $UTOLF
TraceSafe Inc. (TSF in Canada, UTOLF in U.S. with OTCQB listing in near future) Industry: Real-Time Location Services (including Contact Tracing) Notable Management: Mr. Wayne Lloyd (C.E.O. of TraceSafe) Dr. Dennis Kwan (C.E.O of TraceSafe Technologies), Why We Love it: By the time I finished my DD, and I did quite a bit of it, TraceSafe was an auto-buy for me and a pleasure to write about. But before diving in, I had questions; plenty of them. I believe that investors should enter every opportunity with skepticism. It gives you a clearer head and reduces potentially dangerous levels of FOMO (fear of missing out). FOMO can drive valuations of stocks to scary levels and it rarely ends well, as retail buyers like you and me buy the hype on a company while bigger players exit their positions. Smaller growth-oriented companies can often have new, exciting technology that captures the imagination of the market, but smart investors, retail or otherwise, always look for one key milestone before buying in: validation. Without proof that a company is successfully penetrating their market, you’re buying the idea instead of the reality. When I first looked at Tracesafe in the autumn of 2020, I was impressed by the technology they were bringing to market with an experienced management team. But I didn’t invest my hard-earned money because I needed to see real partnerships with big-market companies. Cutting edge technology, for all its impressiveness, isn’t worth much to a company without the means to monetize it. If you’re buying the idea, you’re making a leap of faith, and that is a little too close to gambling for me. So much has happened since then that the leap of faith has become an open door to walk through. Validation is here. But before we get to all that, let’s set the foundation, because none of this would have been possible without the management team, which is one of the most impressive parts to the story. The C.E.O., Dr. Dennis Kwan, and The C.T.O. Suresh Singamsetty, have been developing technology companies in the wearables space for years. Dr. Kwan co-founding Martian Watches, the first ever voice-enabled smartwatch. He was also V.P. of a Bluetooth company that was acquired for $160 million and he personally owns more than ten patents in wireless/bluetooth technologies. Mr. Singamsetty, the software expert, was with Dr. Kwan at Martian Watches. He owns more than 20 patents himself. The third member of the team, Gord Zeilstra, is another massive successful industry veteran. His specialty is driving companies’ global sales footprint. His success in the building of Monster.com and S.A.P. into global brands is an exciting indicator of where TraceSafe is headed. So what about validation? Let’s begin with its partnership with Tritan Software. You probably haven’t heard of them, but I have no doubt you have heard of Carnival Cruises, Norwegian Cruise Lines, and Royal Caribbean. Tritan is the health and safety software provider for 95% of the entire global cruise line industry. I’ll put that in word form to give it the attention it deserves: NINETY FIVE PERCENT of the global cruise line industry. Tritan is responsible for collecting, storing and securing the privacy of health information for all passengers, in addition to quality and incident management and a host of other software solutions. The CDC (Centre for Disease Control and Prevention) will most certainly have compliance requirements for resumption of sailing operations and Tritan knows this, which is why they are acting now, and acting swiftly. (Countless other companies approached Tritan, but they chose the experience and superior security of TraceSafe). The partnership was only recently announced and it remains to be seen how entwined the two companies will become, but contact tracing is only the tip of the iceberg (sorry, not the best cruise line analogy). For a clearer picture of the entire iceberg, we can look to Walt Disney’s iconic theme parks. It is no secret that Disney theme parks have always placed a premium focus on customer experience, and one of the most effective ways they achieve this is through the “Magic Band”, which is essentially a wearable device that customers use to enter the park, unlock their hotel rooms, and buy food and merchandise. A one stop shop on your wrist. This is where the cruise industry is headed. With a wearable on your wrist, you can enjoy all the same conveniences as the Magic Band combined with a contact tracing and safety monitoring device, all in one device. So, that’s it? The cruise lines? Even if it were the only partnership in the pipeline, it may have been enough to turn TraceSafe into a major global player, but it is just one of many projects, both ongoing and in the future. But even greater validation was announced just today (making me do some quick edits to this story) TraceSafe, just today, announced a potentially game-changing purchase order. The agreement is to supply a global Tier 1 semiconductor manufacturer with 60,000 wearable units to be used across their enterprise. Professional services network Deloitte is managing the implementation of TraceSafe’s “next generation” of wearable products, which can be processed and paired within seconds, compared to about 3 minutes per device of other companies in the industry. To give you an idea of the magnitude of this agreement, Dr. Kwan is quoted “This is one of the largest deployments of its kind anywhere in the world and we are very proud to be working with technology innovators to deliver a product so important in enhancing the health and safety of their workforce.” I will forgive you if you stop reading now. The above agreement, combined with the cruise line partnership, is honestly enough for me and for many investors, but for those who stick around, the story actually gets considerably better. The total wearable market is projected to reach $60 billion, and a large part of this will focus on corporate safety. In this way, Tracesafe has a bit of an advantage, as the company has a presence in Southeast Asia. You will remember that long before we realized the impact of the pandemic, several Asian countries were already scrambling to deal with the first wave. Since that time, we have dealt with each wave several months behind Southeast Asian countries. This time lapse has given TraceSafe a window into near-future conditions in the Western world. The best example of this is in Singapore, where they are closer to emerging from lockdown than we are in North America. Singapore has become the proving ground for TraceSafe technology., and it has gone perfectly. TraceSafe is being worn on construction sites for Boustead, a massive Singaporean construction company. This partnership has not only led to improvements in safety and security at Boustead, but it has also won TraceSafe the Singaporean National Innovation Award. Closer to home, TraseSafe partnered with The World Junior Hockey Championships in Vancouver, Canada in December. The tournament was essentially a bubble-event that was completed safely using TraceSafe technology. T.T.G, the sponsorship firm that organized the event (and, incidentally, was instrumental in bringing The Winter Olympics to Vancouver in 2010) was impressed. So was Telus, the tournament sponsor. The future is very bright in venue tracing, with fans itching to return but needing a safe and proven way to do it. There remains one incredibly large catalyst for growth, and some may find it the most interesting of all, but before we get to that (cough, Airbeam, cough), let’s quickly dispel any lingering doubts you may have: Aren’t those wrist bands uncomfortable and a nuisance? This is another part of the reason Tritan and others have chosen TraceSafe. Recall that two of the management team are pioneers of the wearable space with over 30 patents between them. The TraceSafe product has a battery that long outlasts any other in the industry and it is also incredibly lightweight and unobtrusive. Added to this is the extended product line, with tags and credit-card style devices. Discounting everything else in the pipeline, is anybody seriously going to get back on a cruise ship after all that has happened? Will the return to cruise lines be slow? The high amount of bookings for the second half of 2021 says “no”, and so do experts in the field, who state that cruise line demand is higher than most other industry segments. Once people are vaccinated, the industry will return in a big way. Tritan understands this; hence the quick action. But what about privacy? Isn’t this just another way for companies or governments to spy on us? I honestly wondered about this because it seemed an obvious question, but the answer makes complete sense. If the TraceSafe software were downloaded onto your phone, perhaps there would be more skepticism on my part. We all value privacy and bristle when it is infringed upon. But these devices are only work-site specific, meaning that the wearables (and software embedded in them) are separate from your personal devices and they do not function once you leave the site. They only ensure health and safety through workplace tracking. Aren’t margins higher on software than hardware? Will this make enough profit? The answers to these questions vary, but they all begin with “yes”. Margins are indeed higher on software, and TraceSafe in fact is currently selling 50/50 between hardware and software (cloud computing), with a focus on moving to 20/80 in the coming months. The cloud-based real-time monitoring system does not, in fact, need an internet connection (which I’d say is important when you’re out at sea) as it is a bluetooth device. No user information is stored on the device and it has medical-grade privacy/security (remember the company’s origins). The administration functions are user-friendly. What about the revenues? Whatever exciting news you may hear about a company, it is always more reassuring to see actual revenues pouring in, even so soon after developing a contact tracing solution. TraceSafe could be forgiven for only being a quarter or two away from meaningful revenues, but luckily for investors, this isn’t the case. Based on video interviews in January, the company expects to continue their 100%-200% year over year growth, which puts them somewhere between a projection of $20-$32 million for 2021. Although it should be noted that I’m extrapolating these numbers by following growth patterns from previous quarters, this DOES NOT INCLUDE ANY NEW PARTNERSHIPS, INCLUDING THE AGREEMENT ANNOUNCED TODAY! (Oops, sorry. I seem to have left caps lock on there!). And then there is the share float. Fully diluted, after all outstanding shares incentive-based options, the total share count will be under 70 million. This is a very small float, which appeals to most investors, as a company in a growth phase will have fewer obstacles to share price growth. What about data? Data monetization is big business. TraceSafe will have the ability to monetize data from their cloud-based software at some point in this process, although that shouldn’t be confused with personal data, which would never be shared, obviously. But corporations looking for trends in safety and efficiency would most definitely benefit from the analysis of general workforce data. What else am I missing? This is a bonus for the company that cannot be overstated. Airbeam. Ever heard of it? Before you read the bonus paragraph below, note that TraceSafe has invested into Airbeam and owns an impressive 9.9 million shares. Ok, go ahead and read about Airbeam now (Thanks to Stock Fam discord user “Aberdenov” for the assistance) The 5G revolution is upon us. This revolution will be in the tens of TRILLIONS of dollars. Airbeam will be a player in 5G critical infrastructure. Their 5G micro cell network utilizing AI/ML with EDGE computing on the 60Ghz band will be a catalyst for smart cities enabling such things as autonomous vehicles. Airbeam will also be deploying wireless cameras with unlimited storage and smart displays for advertising. The company is led by former executive and head of research and development at Qualcomm, Dr Karim Arabi, and along with Stockwell Day and his political connections, the future looks bright for the company. Airbeam's last private raise was back in 2019 with a valuation of 97 million. Since then they have gained traction with pilot projects in America, Qatar and the Philippines. An IPO is expected sometime in 2021 with a far higher valuation. TraceSafe has openly talked about increasing shareholder value after the Airbeam IPO, including a potential dividend, which is unheard of for a growth tech company. So you see how skepticism can lead to the DD that you need to uncover a company like TraceSafe. It has the management team, tech cutting-edge technology, the validation, the contracts, the blue-sky opportunity of an industry that will be a part of our lives, and an incredible piece of foresight to buy in early to a very hotly anticipated IPO. Just another Stock Fam favourite! Thanks to expert poster Jethro and all the members of the TraceSafe channel for their relentless DD. Come join the discussion! Follow me on twitter MrDotto5
I finally had a chance to read the transcript from today’s earnings call from Schnitzer. Here are the key takeaways: “global raw material prices rose to multiyear highs by the end of the quarter driven by strong recovery in automotive demand, supply chain restocking, a resilient construction market and scrap supply constraints related to COVID-19 restrictions. More specifically, ferrous export price increases off the East Coast were positively impacted by stronger export demand for Turkish steel products. Through October, Turkey's crude steel production had increased 4.2% year-over-year as steel production returned to pre-pandemic levels to meet higher domestic and export demand while ferrous scrap imports into Turkey were up 19%. Ferrous export price increases off the West Coast were driven by strong semi-finished steel import demand from China and higher steel production in Asia. A key global driver for the increase in West Coast ferrous export prices has been China's increasing steel demand and China's new ferrous scrap import standards, which have reclassified ferrous scrap as a recycled raw material. We expect this to create higher demand for global ferrous scrap.” “U.S. domestic prices were underpinned by similar trends. The latest U.S. economic data reflect durable goods orders, industrial production and housing starts rising in November. Ferrous prices have now reached their highest price points in a decade. December's global auto sales doubled from their April lows and were in line with pre-pandemic levels. Current auto inventories are at 10-year lows. Container shipping is experiencing its strongest demand in at least a decade and some steel order books stretch into March and even April.” HIGHEST PRICE POINTS IN A DECADE - closing in on 2008 levels - THIS IS HUGE - also lining up going back to my original post to kick off this entire steel series of posts. Current auto inventories - 10 YEAR LOW What does that tell you? Tells me that steel and more importantly steel stocks are going to 🚀 further and further until there is relief. As of now, I don’t see that coming until Fall at the earliest. More from the call: “The recent sharp increases in ferrous and nonferrous prices have been driven by low inventory levels after many quarters of destocking, followed by significantly higher steel mill and smelter buy plans and production levels. There are also many LONG TERM trends that support strong and sustainable ferrous and nonferrous scrap demand including the transition to lower carbon technologies, China's elimination of quotas for nonferrous scrap imports that meet its metal content standards and the prospect of China's reemergence as an importer in the global ferrous scrap market. In a world that is seeking decarbonization, we expect recycled scrap metal to be an increasingly important metals carbon solution and for demand to accelerate.” CHINA. CHINA. CHINA. Their need for steel is unquenchable at this point. Then you have the rest of the world - THAT ALSO NEEDS STEEL AND RAW MATERIALS. Back to the call: “Global demand for recycled ferrous increased in the first quarter which was driven by continuing economic recovery, benefits of government stimulus and concerns over tight supply. Our flexible operating platform, our logistics expertise and our global sales reach, all helped us to maximize the benefits from this heightened demand. We shipped 63% of our ferrous in the quarter to the export market and we sold the remainder into the domestic market. Our top total country destinations for ferrous exports were Bangladesh, Turkey and Vietnam.” Wait until China purchases start. I expect deals to be done soon and a new benchmark will be set. Back to earnings from the call: “Our adjusted EBITDA in the first quarter was $40 million. This performance was up significantly from $28 million in the fourth quarter of fiscal 2020 and was quadruple the adjusted EBITDA in the prior year quarter. The combination of improved market conditions and benefits from management initiatives led to an expansion of our operating margins. Adjusted EBITDA per ferrous ton reached $38 taking us to pre-pandemic levels last achieved in fiscal 2019. This also represented a sequential improvement of $11 per ferrous ton. Around half of that increase came from improved markets and the other half from actions we have taken. These included our commercial initiatives and productivity improvements which were enabled by our new One Schnitzer organization model and a benefit of $2 per ferrous ton from a sales contract settlement. Benefits in the quarter from average inventory accounting were approximately $2 per ton. This compared to a similar impact in the previous quarter and an adverse impact of $4 per ton in the first quarter of the prior year.” Bottom-line Schnitzer blew past all expectations, as I had predicted. Paper hands sold the news. However, the AH market popped up again. This is a $50 stock in short order and has legs to reach $60. I think it reaches back into the low $40’s next week and possibly hits blue sky $43+ mid next week. The MOST IMPORTANT thing to take away from this call is that steel is reaching levels we have not seen in over a decade based on scrap and raw material costs. This will translate to higher steel prices = higher revenues = higher margins = higher EPS. 2021 WILL BE A STEEL SUPER-CYCLE. TL,DR I like this to hit $50 soon. I took a gamble and bought $40 calls expiring next week when it bottomed out late today from its highs. I’m betting on a bounce and then blue sky. Good luck and do your own research.
Is BigToken one of the most undervalued penny stocks in the market?
I want to thank everyone else who takes the time to write out thoughtful and truthful DD’s, this shit is like writing a college final research paper the night before it's due. It’s a little scary to think your reddit post could influence someone to spend, and potentially lose, money on a stock just by taking your word and not researching on their own, so this post is definitely not advice and I am definitely not a financial advisor. This is simply a think piece that is open for discussion. I’ll link all sources to my information below. You may not have heard of BigToken. I barely noticed it’s vague ticker $FPVD as I was scrolling through the TSNP Stocktwits feed, wondering how TSNP blew up. A fashion tile company? Oh wait no, an app named HUMBL that hasn’t been released yet, something about blockchains, a ticker change and reverse mergers… I never really took an interest in it and thought it seemed suspiciously pumpy as it saw gains from $0.16 - $1.70 in one month, but like it or not the retail investors had made a statement. I am neither bullish nor bearish about TSNP, however as pointed out by an author at SeekingAlpha the blind enthusiasm of some fans was reminiscent of the electrolyte scene in the movie Idiocracy (TSNP’s electrolyte = blockchain).
Attorney General: Brawndo's got what plants crave. Secretary of Energy: Yeah, it's got electrolytes. Joe: What are electrolytes? Do you even know? Secretary of State: It's what they use to make Brawndo. Joe: Yeah, but why do they use them to make Brawndo? Secretary of Defense: 'Cause Brawndo's got electrolytes.
Truth be told I have a vague familiarity with things like cryptocurrency, blockchains, and crypto wallets, but it’s becoming increasingly obvious that crypto is the future. It’s legitimacy is evolving by the day - for example just 5 days ago Tesla bought $1.5 billion worth of Bitcoin and is now accepting it as a form of payment. While I was mindlessly swiping the TSNP feed a few days ago, I noticed this ticker being cross posted: $FPVD. I almost disregarded it at first, the ticker letters did not stand out on the feed and I’m wary of what is posted on there. When I finally did decide to click on it, the company’s name was Force Protection Video Equipment Corp but the comments were flooded with information about a reverse merger with BigToken and parent company SRAX Inc. BigToken is a 4-star rated passive income app on the AppStore. Essentially, “BigToken is the app to own and sell your own data.” Data privacy has become a hot button issue in the age of Facebook and Google watching and selling your every move, we all know the warning “if the service is free, you are the product.” And that’s true with BigToken too. We are the product and have always been the product, but at least here’s an opportunity to get paid for it. You choose to give permission about what data to submit via options like surveys and questionnaires, linking your social media, enabling location, and then this data is then sold to advertisers. BigToken has an established clientele list with a 100% retention rate. The results of a case study for their client Kraft may give you a glimpse into how their business works: Case Study: Kraft Heinz Instant Pot Meals at Publix
Result: BIGtoken closed the loop, utilizing the platform and panels to measure campaign effectiveness. ●This campaign had the highest recall rate of all channels, outperforming in-store tactics as well as digital offer tactics like Shopkick. ●45% of reported Instant Pot Meal Kit purchases at Publix. ●84% of shoppers who saw BIGtoken’s ads said they did or were likely to purchase an Instant Pot Frozen Meal Kit at Publix. ●Social media had the greatest advertising recall, reporting a total of 16K+ likes, comments, and shares, plus 21K+ clicks to Publix.com. In addition, it exceeded the total impressions goal by 17%. ●BIGtoken’s proprietary panels were leveraged to create insights, audiences and data that Kraft Heinz will use to drive future sales
Okay, so let’s recap. BigToken, a previously privately owned subsidiary of SRAX Inc. with 16 million app users has chosen to become public by way of reverse merger, acquiring the shell share structure of FPVD, and in the process has avoided going through an expensive and time consuming Initial Public Offering (IPO). They are in the AppStore, the reverse merger has been completed and they pay users via PayPal or gift cards for their data. They are currently under the ticker of $FPVD, and are releasing their 8-K any day now with a ticker change on the way. Great. All of this is fine and dandy, but I wasn’t really convinced to invest until I researched their CEO Lou Kerner. Lou, a crypto and data privacy advocate, former Wall Street analyst, angel investor and businessman, lurks Reddit. So if you’re reading this Lou, my mom says hi. He has written thoughtful articles about GME and WallStreetBets, cryptocurrency, and the stock bubble we are currently in. By a combination of chance and tragedy (the CEO before him sadly passed away), he was announced as BigToken’s new CEO on January 24th, 2021. If you read his article, 5 Reasons Why I’m Joining BigToken as CEO, you are hearing from him directly. It’s an illuminating piece about the direction of this app. Until now, BigToken has only paid customers via Paypal or with giftcards. Lou is here to take this app from crypto-adjacent, to crypto-centric. His ideas are to provide users with the option to be paid in crypto, in addition to providing a digital wallet meaning the app could expand exponentially. He has mentioned it would be at little to no cost to create BigToken’s own stablecoin. If someone like me who is crypto-clueless can see the massive amount of potential in this app, I would love to hear from someone who really knows what they are talking about. If TSNP/HUMBL has value at $1.40 a share without having an app, why would that not be out of the realm of possibility for BigToken? The Cons: * Penny stocks are inherently volatile. * The market has a mind of its own and everything is a gamble. * The share structure BigToken inherited from FPVD is not the prettiest. Take a look at the SEC filings - as of yet the 8-K has not been released so whether there will be a s is a big concern. * With promising penny stocks come pump & dumpers. * The app could flop. The Pros: You can make passive income on this app. If you used that money to buy a few shares of BigToken, your money can make it’s own money and you could be tumbling blissfully away in a money making washing machine. If and when the stock market bubble pops, this doesn’t seem like a bad investment to hold.
With 16 million users across 30 countries, BigToken has generated 2.2 million in revenue in their first full year as an app (2020), and is only set to grow with a projected revenue of $400 million in 2022.
Cryptocurrency is trending and the deep value is being recognized.
The release of the 8-K and ticker name change have not yet happened, and relatively speaking BigToken is still under the radar.
Gig data and business analytics solutions is a booming business, one that is projected to reach $260 billion globally by next year.
The cryptocurrency market was valued at USD 1.03 billion by 2019 and is projected to reach USD 1.40 billion in 2024
To quote Marx, “I’ve been speculating”. I’ve started to get into the madness that is WallStreetBets and options trading. Now as a Marxist, it feels dirty, but “to survive in a capitalist world means to survive by capitalist means”. While making a few bucks here and there is good, I’m more interested about what wallstreetbets represents. I’ve come to think that it’s almost equally a rejection of capitalism as we know it, and a blind embrace of it. I know, contradicting. One one hand, it’s an embrace in the sense it requires faith in the system. One must believe one can make money in the market. It relies on global capital being successful. Much the same way workers in the global north are complicit in global capital by investing in 401ks, so are we chasing tendies on Robbinhood. Capitalism doing well is good for investors. However when you dig deeper (not even much deeper really), you start to see something else. There’s an apathy, a disregard, and a disillusionment with the capitalist system. The idea that being a participant is enough to “make it” is dying. The vast majority of WallstreetBets users aren’t DeepFuckingValue they’re small fries. They throw a few hundred bucks or a few thousand into a meme stock and hope for the best. While some are doing their due diligence, it would be dishonest to say most are. Most are following trends and YOLOing their 9-5 wages on a meme. Why? Because they feel defeated. They don’t feel like they can make progress through the traditional channels given in capitalist society (jobs, entrepreneurship, etc). So they gamble. They take a chance to get out of the race. Even if we look at the professed goals for many of the investors, it isn’t to corner a market, or to get enough money to start their own business, no. It’s to get enough money to get the fuck out of the game. Of course at first glance this is consumerist (tendies, Tesla’s, buying wife’s boyfriend a car, etc) but the real goal is to get the fuck out. Any way, I find it interesting. Capitalism has grown to a point that many see it as an inevitable reality, the framework for the world, that even when they acknowledge it has failed them and their generation, people would rather YOLO their meager savings into the craps table that is the market, than try to invest that money in a more traditional way (holding stocks, investing in a business, etc). Which brings me to related point that the lefts messaging is still shit. These are very much people ripe for radicalization against capital. Instead of looking to another possibility (leftist ideas) they have decided to say fuck it and gamble on capitalism. It’s very interesting. I recommend checking this video out to see what I mean. I think it shows my point well enough. https://reddit.com/wallstreetbets/comments/l1u036/wsb_gets_emotional_on_mad_money/ Anyway, if GME blows up, I’m donating most of my earnings to revolutionary movements in the global south.
Once again, the Calvary comes to the rescue. Americans can now heave a sigh of relief after months of having to watch their fate hang in the balance as both Democrats and Republicans sparred over stimulus. After foot-dragging and name-calling for several months, Congress decided to approve a $600 stimulus package. However, the incoming Biden administration has promised an additional $1,400 making the total of $2000 in stimulus to be received by Americans. As expected, some of that money would find its way into the stock market. The explosion of retail trading made possible by apps such as Robinhood and Etoro has meant that more people can trade in stocks for zero or little commission. Flush with cash from the government, people are trying to the stock market to increase their money. Based on the prevailing macro-economic conditions, financial valuation, and social trends, we have compiled a list of stocks you should be spending your $2000 stimmy on. DraftKings As more states become amiable towards online gambling, one of the stocks which would benefit from expected legislation would be DraftKings. The expanding legalization of digital sports betting is an emerging trend. The November election results showed voters in several states largely approved ballot measures that legalized sports betting and other gaming expansion measures. On the revenue side, DraftKings saw a 98% year-over-year surge to $132.8 million in the latest quarter, reported on Nov. 13. In the quarter, the company raised its full-year 2020 revenue range to $540 million-$560 million, which equates to 25%-30% annual revenue growth. DraftKings also introduced 2021 revenue guidance of $750 million to $850 million, which equates to 45% year-over-year growth using the midpoints. The resumption of major sports such as the NBA, MLB, and the NHL in the third quarter, as well as the start of the NFL season, has generated tremendous customer engagement and revenue which implies that this stock would definitely see some significant upside. Square 2020 was a very good year for Square. The company’s share price soared above 250% last year and was one of the pandemic winners in the market. Given the company’s fundamentals, Square's stock price will repeat the type of growth it saw in 2020. The services that Square provides -- particularly its Cash App, which allows people to send and receive money without physical contact -- have become more necessary during these times of social distancing and working from home. Revenue for the Cash App was up a whopping 574% year over year in the third quarter. The company is also invested in bitcoin having out in seed capital in acquiring bitcoin. With bitcoin estimated to cross the $40,000 mark and possibly running as far as $146,000, this would shore up the company’s reserves. GM One reason why investors have been wary of the EV sector is the mounting debt and huge cash burn. This has made investors question the profitability of stocks in the electric vehicle space. With more EV stocks coming through the market through SPACS, investors are already mulling the idea that this may be a bubble. However, one company that many believe to have potential in the EV space is GM. Apart from having the infrastructure necessary to build cars, the company is can leverage its brand to ensure loyalty from customers. In addition, while other EV stocks such as Tesla and NIO may be fully stretched, share prices of General Motors are cheap, plus the company is been raking in profits. In November, GM announced it plans to invest $27 billion in EV and autonomous vehicles through 2025. GM also plans to release 30 EV models globally by 2025. For comparison, Tesla currently has exactly four EV models. Earlier this week, the company signed a deal with Microsoft for its autonomous vehicles. GM continues to execute well on its Core and Future businesses and remains one of the best-positioned companies in our coverage over the long run. The stock is a good buy for the long haul. AMD As the digitalization of the world continues at an astronomic pace, microchips would continue to play a more prominent role. Already, there is a shortage of chips worldwide which means demand and prices would surge. One company poised to benefit from this growing demand is AMD. The company has managed to chip away at Intel's CPU dominance thanks to its superior product line, which is based on a smaller manufacturing node, allowing it to deliver better computing performance and reduce power consumption. The use of chips would continue to grow as more people are drawn to cryptocurrency mining, online gaming, and data center storage. AMD was one of the biggest winners in2020, and the trend is expected to continue well into this year. It is also one stock that may not be affected by the rotation into value as microchips would continue to be in demand. TSM Taiwan Semiconductor is a dedicated foundry that manufactures semiconductors for other companies. It aims to lead in both semiconductor technology and manufacturing, providing an open collaboration platform to build enduring trust with its customers. The core strategy of Taiwan Semiconductor is its flexible business model. TSM does not need to design its own chips and prove its performance against the competitors; it only has to provide the technology and base for producers looking to make the best and fastest chips suited to their products' needs. By maintaining high-quality manufacturing processes and offering a collaborative platform to its customers, Taiwan Semiconductor ensures that it caters to producers across the spectrum even as technology rapidly evolves. The company has experienced strong growth: From 2015 to 2019, net revenue increased by a solid 26.9%, while net income increased 12.7%. However, as smart technology has become ever more central to lives the company's growth has begun to heat up. In Q3 2020, the company boosted its net revenue by 21.6% year over year, while net income increased by 35.9%. ETSY Etsy provides an online e-commerce platform where creators of arts and crafts, vintage items, and other unique goods go to sell their products. Etsy has something that many high-growth companies don't -- a profitable business model. It boasts a trailing-12-month operating margin of 16%, making this unique online marketplace a buy today even at its premium valuation. It has outmaneuvered eBay (EBAY), avoided the Amazon (AMZN) crush, and dodged competition from Overstock.com (OSTK) and Wayfair (W). When it reported third-quarter results on Oct. 28, Etsy reported a 128% leap in revenue to $451 million, well above Wall Street estimates of $412.7 million. Adjusted earnings came in at 70 cents, vs. estimates of 57 cents. In addition, gross merchandise sales jumped 119% to $2.6 billion. Sunpower Interest in renewable energy sources has soared immensely and continues to rise with each passing day. Two key forces are behind this surge: Increased awareness and urgency to address climate change, and falling costs of generation using renewables. Among renewable sources, solar energy looks most promising, due to its more predictable generation pattern. Solar's share in electricity generation is expected to rise from roughly 3% currently to more than 20% by 2050. SunPower (NASDAQ: SPWR) is one stock poised to benefit from these trends. With a huge government push, California leads the way in solar adoption. Still, only 9% of homes in California have solar installations, representing a huge untapped market. In the new homes segment, SunPower has headway, having already worked with 18 of the top 20 builders in California. The company captures more than half of California's new homes market. Its low-cost model positions it well to compete on pricing. The company can leverage its vast customer base to sell its storage products. Moreover, its leading position in the commercial and California's new homes market provide SunPower an edge over others in these segments. PLUG Plug power provides hydrogen fuel cell turnkey solutions to electric mobility and stationary power markets. The company continues innovating end-to-end hydrogen fuel solutions by harnessing its unique capabilities and is the largest buyer of liquid hydrogen in North America. Though the company has not posted any profit, many hedge funds are bullish on the stock, with analysts having high recommendations. The company’s $1.5bn deal with South Korean conglomerate SK Group into American hydrogen company has certainly drawn a lot of attention, with many investors gauging the company’s profitability. Plug Power’s core business is providing fuel cell-powered forklifts for commercial customers. However, it has expanded to hydrogen production following its acquisition of two hydrogen companies. These acquisitions expand the plug’s addressable market which has already exceeded $30 billion. The resulting vertical integration of the acquisitions makes Plug Power an even stronger company as can now provide the hydrogen that powers its vehicles. This definitely allows Plug to leverage on its already existing customer base which includes some of the best companies in the country. Plug Power raised its 2024 guidance to $1.2 billion in revenue and $200 million in operating income. Shares of PLUG have risen by 111% in the last month. Tesla Returning to the green-energy theme, Tesla is one stock that has significant upside. The company is positioned to benefit from the clean energy drive of the Biden administration. Apart from that, Tesla is the leader in its sector and continues to increase its delivery numbers. Tesla is now the most valuable auto company in the world. It has recently surpassed Facebook (FB) by market capitalization. The stock has recently received upgrades from analysts and if the EV market continues to evolve, Tesla would continue to be in the pole position, which gives it significant market share and of course revenue. GrowGeneration Corp. For those looking at balance sheets and income statements, GrowGeneration Corp is one highly profitable marijuana stock to watch in 2021. The company has the largest chain of specialty hydroponic and organic garden centers in the U.S. with 36 storefront locations. In essence, the company supplies products necessary for growing cannabis and works closely with major marijuana companies in the U.S. market. Shares of Grow Generation returned a whopping 880.98% in 2020, posting the fastest-growing quarterly results in the industry. It is expected that the company would continue its momentum this year. The shares of the company have so far risen by 20% this year. Additionally, the company continued strategic acquisition and expansion plans in the quarter, giving GrowGen more growth potential for 2021. It was easily one of the best performing cannabis stocks for 2020. In essence, GRWG stock showed greater market stability than other pot stocks in the U.S. in 2020. Thanks for reading! Checkout Afroxyz's page for more.
Comprehensive DD on $CTYX: The OTC Biotech Stock of the Decade That Is Being Slept On
[Connectyx (OTC-PINK: CTYX). Will change to Curative Biotechnology with ticker $CURB in Q1 2021.] I posted this on pennystocks yesterday. Full Disclosure: I have a $6k initial position in this stock at a cost average of $.06. The stock is now at $0.155 (as of 2/6/21) with my position at $15.5k and movement is just starting. I am not a financial advisor. I am simply a broke graduate student interested in investing and fucking retiring early. This post represents my personal views and should not be taken as financial advice. Do your own damn research and stop pumping your hard-earned cash into trending stocks on Reddit posts that are nothing but hype, rocket emojis, and a mob chat jerking each other off. Also, not a doctor! The medical content below should never be a substitute for professional medical advice. With that said, $CTYX is going to fucking Pluto 🚀🚀🚀🚀🚀🚀 🌑 Price Target: $0.5 by May 1, 2021; $1.25 - $3.00 (~10x) within 2 years with credible potential to be listed on NASDAQ. This company is absolutely solid on all sides: healthy financials, an experienced & reliable management team, favorable market conditions with a reasonable business model, a solid lineup of products in its pipeline, and many large announcements anticipated within the next 3 months. Simply put, there is extreme asymmetric upside. $CTYX or Connectyx was taken over by its current team led by CEO Paul Michaels around Feb 2020. Within a year, this CEO has kept every promise he's made and established the infrastructure for growth. The company specializes in bringing orphan drugs (more on this below) through clinical trials and then to market. Paul and his team have decades of experience in big pharma, biotech research, finance, and drug licensing/development (in-depth description in the Management Team section below). They've vetted 3 promising drug candidates in under a year and promised to start clinical trials by mid-2022. If any one of these pass phase 1/2 trials, the market cap grows by hundreds of millions. They also have a reasonable chance to obtain a Priority Review Voucher (PRV) from the FDA that is worth $100-$300M from their strategic picks. They have a clean balance sheet, acquired non-dilute bridge financing while putting these drugs through trials, and have plans of additional deals in the near future. Why orphan drugs? Orphan drugs are therapeutics that treat rare diseases (defined as illnesses affecting less than 200k Americans per year). From the Orphan Drug Act, there are multiple incentives given by the government to develop orphan drugs: (1) significant tax credits (2) longer market exclusivity after approval (3) waiver of certain FDA fees (4) easier & faster approval process. In 2019, the global orphan drug market is estimated to be valued at $151B. By 2027, this is projected to reach $340.84B (10% compounded annual growth). This the cornerstone of their business model. By gathering a group of experts, they can cheaply vet high potential candidates to add to their development pipeline and then commercialize them from reduced fees as well as fast-track benefits from the FDA. So why the hell is it call Connectyx? It is just the old name of a software services company which the team acquired. The company has filed for a name change that will be granted within the next 2 weeks to Curative Biotechnology Inc. with a new ticker $CURB. In addition, the CEO himself has hinted at an uplisting to $OTCQB (a certification upgrade from current pink sheet status), mergeacquisition announcements, and $100M in non-dilutive funding. The official FINRA announcement of the name change will be the catalyst for the additional news. Some quick notes about the charts. The 15x jump in the past couple of months is only the beginning. There is a clear trend of resistance breakthroughs and medium-term consolidation after each announcement. Volatility is low, the number of outstanding shares is small, and there is limited dilutive potential for an OTC. Let's dive deeper into this hidden gem. All-Star Management Team CEO Paul Michaels Curative BioTech lucked out with a CEO with 25 years of experience in investment banking with a focus on life sciences. Paul has an impressive record, starting as the Executive Vice President and board member of Global Capital Group (a Wall Street wealth management firm). He also got extensive experience in big Pharma through Inabata & Co. Ltd, a subsidiary of a large Japanese drug company, Sumitomo Chemical Group, which totaled $21.8B in revenue in 2013 and employs over 30k people. While serving as Inabata's CFO, Paul licensed American drugs (some from Gilead) for the Asian market. After, the guy helped create Nobelpharma, an orphan drug company, which licenses drugs for rare diseases and got over $35M in initial capital. In February 2020, Paul took over Connectyx (a software services company at the time) and made it an orphan drug company. It is extremely rare for pink-sheet companies to have such high-caliber, established talent as a leader: decades of experience with finance and leadership positions in multi-billion dollar pharmaceutical companies. He helped build up Inabata and Nobelpharam (both thriving today), and I am confident in his ability to do it again with Connectyx. VP Communications Pam Bisikirski Recently, Curative announced Pam as the new Vice President of Communications. She previously served as the director of marketing of National Vision for 21 years. National Vision ($EYE) is a huge optical retail, eye care, and eye-ware company that is trading near a $4B market cap on NASDAQ. Scientific Advisory Board Dr. Michael Grace [news] - Ph.D. in Biochemistry and BS in Chemistry from the University of Nebraska. 30 years of experience in BioPharma with top roles in names like Procter & Gamble, Schering-Plough, Bristol-Myers Squibb, NPS Pharma, and Advaxis Immunotherapies. Lead 6 products to registration and commercialization. Dr. Ronald Bordens [news] - Ph.D. in Biotechnology with over 26 publications and over 2000 citations. 40 years in biotech and big pharma in research & development. Had a fruitful 26-year career at Schering-Plough Research. Richard Garr [news] - Serves as Director and CEO as well as President of Neuralstem Inc. (now Seneca Biopharma, Inc. which is listed on NASDAQ as $SNCA) for 20 years. Advocate for right to try treatments in the US and Europe. Founded Access Hope CRO (contract research organization) which dedicates itself to this cause. Was founder and current Board Member of the First Star Foundation Mid-Atlantic chapter which focuses on ill children (including pediatric brain cancer). Robust Drug Pipeline Keep in mind this company became a biotech firm in Feb 2020 and they already have 3 drugs in the pipeline along with exclusive rights licenses. Insane. 1) IMT504 immune therapy to treat late-stage rabies. (11/23/2020 Announcement implies IMT504 rabies license deal is complete) Strategic relationship with Mid-Atlantic BioTherapeutics, Inc. announced on 8/27/2020. Acquired all rights for development of this patented immunotherapy to treat late-stage rabies (a disease with 100% fatality rate after the treatable period, [kills 59k](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613553/#:~:text=about this topic%3F-,Each year%2C rabies causes approximately 59%2C000 deaths worldwide%2C including approximately,of postexposure prophylaxis (PEP).).)) globally per year). Now, the value of this may not be in the drug approval itself (although passing trials would be a huge asset of course). The value is the potential in CTYX obtaining a Priority Review Voucher (PRV). These coupons are handed out by the FDA each year to incentivize research into rare diseases. Exercising the coupon means diminishing the approval process from 10 months to 6 after trials. Further, you can freely sell these on a secondary market to other companies! Historically, these have been sold between $100M to $300M each. If obtained, this is an instant 2x-6x increase to its current $50M market cap. There's more.. notice that the FDA has added Rabies to its PRV-eligible tropical diseases list. Currently, there is only a handful of rabies therapies being researched. This means there's actually a good chance of CYTX getting rewarded a voucher, despite the relatively low count of vouchers distributed annually. PRVs are also possible for all other drugs in the pipeline. 2) CURB906 monoclonal antibody cytotoxic conjugate for the treatment of Glioblastoma. (10/16/2020 NIH gives a grant of license for worldwide rights) The second license was filed near July 2020 for a novel monoclonal antibody conjugate to treat brain cancer. Glioblastomas are aggressive brain tumors with poor survival rates in children. Recent studies (e.g. s1, s2) have shown different combinations of chemo-therapy and antibody-drug conjugate (ADCs) therapeutics were effective in both mice and human models. ADCs are innovative methods that attach a cytotoxic compound (one meant to kill cancer cells) to an antibody that specifically attaches to certain cancer cell receptors, thus delivering therapies to their targets. There is great promise and lots of potential in these therapeutics. Exclusive Evaluation and Commercialization Option License Agreement with the National Cancer Institute (NCI) has been granted. 3) Metformin repurposed to treat retinal degeneration. (2/4/2021 NIH gives a grant of license for worldwide rights) This is probably the ace in the hole and the largest reason behind the recent stock surge. On 2/4/2021, CTYX announced they received an NIH grant for exclusive worldwide rights to adapt a diabetes drug, Metformin, to treat retinal degeneration. Not only is Metformin proven safe (it is a widely used drug to treat Type1 Diabetes since 1995), there are many studies (e.g. s1, s2, s3) that hint at its effectiveness for retinal diseases. The recently granted license not only covers pediatric retinal generation (in the form of Stargardt Disease), it covers treatment in adults as well and includes macular degeneration. This promising treatment potentially covers 2/3 of the US population (2/3 of Americans are pre-diabetic, 1/10 are diabetic, and 11 million have some form of macular degeneration; why care about diabetes? diabetes causes retinopathy). Huge Upcoming Announcements The announced name change is the opening of the flood gates for all upcoming news. Additional licenses, uplistings, and deals with be done under the new company name. Expect many of these announcements following FINRA approval. These are some forward-looking implications:
(Within 2 weeks) FINRA approval of name change to Curative Biotechnology Inc. and ticker $CURB.
(Within weeks of name change) Following the name change, there will be an uplisting to OTCQB. OTCQB is a tier up from Pink Sheets and must adhere to stricter management certifications, undergo annual audits, and are more stringent in their financial reporting. Connectyx is currently working to become fully reporting OTCQB; to that end, the Company appointed Jonathan D. Leinwand, PA as Legal Counsel.
(Within weeks of name change) Talk of multiple upcoming drugs (if the Metformin announcement was one of them, we should see at least one more).
(Within weeks of name change) Hints at $100M of non-dilutive funding for clinical trials.
(Within months of name change) Mergers, acquisitions, and partnerships with other firms for licensing and commercialization.
Downsides Before we get ahead of ourselves and dream about retiring in 3 months while riding this into space, we gotta ground ourselves and discuss the downsides. Remember: in life, there are no solutions, only tradeoffs. There are always downsides and risks. Risk 1) This is currently a pink sheet. That itself should make you more cautious because there is reduced regulation, more "flexible" rules, and less scrutiny/transparency. Risk 2) High risk, high reward. If all 3 drugs flop (assuming no additional therapeutics are added) and they don't get a PRV (priority review voucher), then this company is worthless. Granted, the chances are low, but still a possibility to consider. Risk 3) Share dilution and raising capital. Because clinical trials often require obscene amounts of capital (~$400M investment for normal drugs), there is a risk that managers might dilute the stock in order to raise money or to take profits in general. There are currently 322M outstanding shares with 1.1B authorized shares. Read the share disclosures, do the math, gauge the risks. Note that orphan drug trials are a lot less costly as well. Risks and unknowns are certainly there. However, the upside potential is too big to ignore. Buy at pennies, sell for dollars. Do the research and take advantage of any dips that might come on Monday from 2 days of green explosions. ------------------------------------------------------------ TL;DR.
You should fucking read it, because this Phoenix has a high probability of rising from ashes to become the OTC stock of the yeadecade with effortless 10x upside in the short-term.
$CTYX will change to $CURB (Curative BioTech) soon. Business strategy: (1) bring together financial experts, veterans in big pharma, accomplished biotech researchers, and world-class grant writers to vet orphan drugs (2) make deals and obtain licenses for these drugs to help get them through clinical trials (3) take advantage of special FDA benefits for orphan drug approval (faster approval process, fee waivers, etc) and commercialize them after with longer exclusive rights.
Finance: company has no problematic debt, clean sheets, non-dilutive funding, and a small number of outstanding shares for an OTC (322M).
Products: 3 promising drug candidates in the pipeline within a year. Multiple exclusive license grants approved by the NIH.
Upcoming Announcements: (1) name change (2) uplisting to $OTCQB from pink sheets (3) more non-dilutive funding (4) additional drug(s) in pipeline (5) mergers, acquisitions, and deals with other pharma companies.
Current market cap: $50M. Upside: (1) +$100M - $300M if awarded a priority review voucher (PRV) (2) +hundreds of millions in market cap if any of the 3 promising drugs goes past phase 2 ~end of 2022 (3) +millions in speculative capital if new drugs are announced in pipeline (4) potential future merger with large pharma or uplisting to NASDAQ (other biotech companies are listed with half the number of products).
Due to the overwhelmingly positive feedback on my last posts, I wanted to provide more DD for you all :) Disclaimer: I wrote the AVGR, OGEN, and CTRM DDs yesterday and had issues with posting. I also wrote all of these before the political unrest in DC. So, if these stocks are down for a minute or if they are unstable, this could also be why.
$AVGR
What is AVGR? Avinger Inc. manufactures catheter devices used to treat vascular diseases. It designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease. They offer products like Lightbox imaging console, the Ocelot family of catheters, and Pantheris. All products are manufactured and sold primarily in the USA but are sold internationally as well. When I’m writing this, the shares are trading for about .64 each. Today they’ve gone up almost 10%, fluctuating a bit. I think anything below .60 cents is a deal. Why are we looking at them? Balance sheets. Sure, they have debt, but they have net cash. Their earnings weren’t incredible, but they were stable over the last year. NASDAQ extension and no reverse split for now. AVGR needs to get above a dollar and stay there in order to stay listed. As of two weeks ago they aren’t considering a reverse split, which is good for us. I don’t see a reverse split playing out due to my next point Volume is going up. January launch of Tigereye CTO device= News. Yep, they have a product launch coming up. This is why I think anything below .60 cents is super cheap for this stock. After the first cases with Tigereye CTO, a doctor said this, “Based on my initial experience with TIGEREYE, I believe this device represents a major advancement over other treatment options for CTOs that will enable a higher standard of care for patients suffering from this severe form of PAD.” This was back in September when they got FDA approval. Now we’re ready to see the launch this month! Literally any day. Final notes: Overall I feel like this is one of the less risky picks of mine. I say get in under .7 and have a plan to get out and you should have a pretty solid chance to make good gains. I’m personally 330 shares deep, and I will take my initial investment and partial profits out when we see 1.10. Then, I’m going to let the rest ride up to my discretion. This way, I get the gains but I’m locking in profits as I go. SUPPORT AT .63, WALL AT .69 PT: 1.10, the sky is the limit (not literally— think like 2 dollars depending) when the product drops, though.
$OGEN
What’s OGEN? Oragenics Inc. is a biopharmaceutical company, which focuses on the development of novel antibiotics and treatments against infectious disease and oral mucositis. Its technology and pipeline is comprised of antibiotics and genetically engineered bacterial strains. Right now it has one buy rating from an analyst which is nice and might be more convincing than my own “buy” rating! This analyst gives it a PT of 2.50, which is a 323% increase from it's current value. Why OGEN? The volume is up 500% from their 65 day average. Wild. They recently closed a direct offering. If we remember patterns from other pennies, we know this can send stocks to space simply by bringing them publicity. Once there’s the publicity and the volume, there’s the FOMO. Then we hit a dollar. Financials. Actually, not bad. Their liabilities have gone down since last year which is a good sign. They aren’t loaded by any means, but this company doesn’t have a ridiculous financial situation that we often see with pennies. See Q3 here: https://ir.oragenics.com/financials Upcoming news. Taking this quote directly from Yahoo finance because I can’t say it better: “December 2, 2020 Oragenics, Inc. (NYSE:OGEN) is developing TerraCoV2, a vaccine candidate against SARS-CoV-2 (the virus that causes COVID-19) that is licensed from the National Institute of Allergy and Infectious Diseases (NIAID). The vaccine candidate is targeted against the prefusion spike (S) protein found on the surface of SARS-CoV-2 (more details below). Since acquiring the rights to the vaccine candidate earlier in 2020, Oragenics has completed the creation of the antigen producing CHO cell line, with purification methods currently under development. In addition, we anticipate the company announcing a deal for an adjuvant to be used with the vaccine in the first quarter of 2021.” So we haven’t seen this deal announced. That's news that could come any day now. In a report last month they said they they expect “the completion of various preclinical studies” during the first quarter of 2021. I found this on Yahoo Finance on the company: “Currently, we estimate that the company will file an IND for TerraCoV2 by the end of the second quarter of 2021, with a Phase 1 clinical trial initiating in the third quarter of 2021.” So these are farther out, but we see again that there is news on the horizon. This gives way to rumors and PR, then to news. Then we sell and get move on. If you would like to read the whole Yahoo article on OGEN from December, here she is: https://finance.yahoo.com/news/ogen-advancement-covid-19-vaccine-143700250.html Try to get in at one of these dips we’re seeing at .55 or so. Next resistance: .59 PT: 2.00 for now but sell when you feel comfortable. I’ll take partial profits at 1 because I always get nervous about these pennies at the 1 dollar mark. The momentum is there. I say it’s a go. Final thoughts: I’m super hopeful here. I don’t see a downside to getting in this one considering what they have on the horizon and the price-point we’re at.
$CTRM
Who is CTRM? Castor Maritime Inc. describes themselves this way on their site: [We are] a dry bulk shipping company. The Company was founded on September 12, 2017. . . Our primary goal is to grow our fleet through acquisitions of new and modern vessels.” They are also described this way on Global Newswire: “Castor Maritime Inc. is an international provider of shipping transportation services through its ownership of dry bulk vessels. The Company’s vessels are employed primarily on medium-term charters and transport a range of dry bulk cargoes, including such commodities as coal, grain and other materials along worldwide shipping routes.” Why are we looking at CTRM right now? Volume. For starters, this ticker has been trading at a considerable volume lately, which is good news when combined with how the charts look. It is on a bullish trend at the moment, probably because it just received a 180 day extension with NASDAQ to stay in compliance with minimum bid rules. Price relative to gain. It’s trading at .24 as I write this, but at open it was trading at .18, meaning that today alone it saw a rise of 29 percent. I expect this to continue because often these extensions result in a rally, and that extension was just granted on the 30th. Also, there’s an offering closing today and the company just bought 2 new ships. Remember— compliance is over a dollar. So if you believe this company can hit a dollar, it’s probably worth an investment because you could easily see 4-5x your money. Pre-COVID value. This stock only dropped under a dollar when COVID hit. It took a special tumble in July during their scheduled maintenance period. I like to think that these stocks that took hits during COVID have extra potential to reach their pre-COVID value or at least creep up close to it. Charts. Over the past few months, CTRM has blown past resistance points and turned those points into new supports. I like the way these look. What’s the risk and bear argument? Dry bulk shipping is at an all time low. I think reading an article about it is a good idea. Whether or not you buy this stock is a question of whether or not you think this crisis is an opportunity or a threat. https://www.maritime-executive.com/blog/dry-bulk-market-crisis-an-opportunity-or-threat Final thoughts: With this one, be cautious. That being said, I won’t argue with high volume and this rally following their extension. I see this as a potential big winner but tread lightly if you’re a more conservative trader. This is a great YOLO buy, though.
$ADXS
At .49 as I write this. What is this company? “Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors.” Tldr; they’re in biotechnology and they work with prostate cancer specifically. After a public offering in November, these shares plummeted, but they’re on a steady climb back to pre-COVID numbers (over a dollar) They need to hit 1.00 for 10 consecutive days sometime before June 21st 2021. Why talk about this stock? With the volume it’s seeing right now, hitting a dollar feels possible. They have 1 buy rating with a PT of 5 dollars which would be a 922% upside. I’m not waiting for 5 dollars on ADXS because in my mind hitting a dollar and cruising to 1.50 would be great. Prostate cancer is a big market. PC accounts for 1/3 of all male cancer diagnoses and 10% of all cancer related deaths globally. Since ADXS targets their immunotherapy at prostate cancer, this is good news for the company. If their products work, there is a market for them. Hedge funds. At the end of Q3, ADXS was in 3 hedge funds’ portfolios. Their all time high was 21. This is low, but News. Earnings coming out 1/08. This is the big one. Earnings will be reported Friday. This is a gamble play. If the earnings are good, we’re on the moon. If the earnings are bad…. well. What does history tell us? Revenue has consistently gone up over the past 4 years. BUT. Net income is still down. They have cash but taxes and operating costs are hurting them. Their liabilities have gone down though. Overall this is a gamble. I’m in it with 192 shares but I’m watching it like a hawk going into Friday. I see a huge upside for my money but there is risk here. More information: https://www.biospace.com/article/prostate-cancer-therapeutics-market-product-differentiation-to-create-fructuous-opportunities/ https://seekingalpha.com/article/4332116-advaxis-is-one-biotech-should-be-on-your-radar-targeting-large-nsclc-and-prostate-cancer-drug
$NSPR
“InspireMD, Inc. is a medical device company, which engages in the development and commercialization of the stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Tel Aviv, Israel.” (though it is headquartered in Isreal, its products are approved for use in the US) Their claim to fame is their micro-net technology with their stents. (https://www.inspiremd.com/en/products/the-technology/) Currently they have 2 products (CGuard and MGuard) and 3 in development. At .49, it gets a buy rating from 2 analysts with price targets of .7 and 1 dollar. Here is the chart for the stock: https://www.tradingview.com/symbols/AMEX-NSP It’s 52 week range is .28-1.64 with those highest prices being seen last year in early Q1. Directors own shares price points of .45 and .50. Hedge funds are getting interested in this stock. The volume for this stock is increasing daily. Just 2 days ago it was at 38m and the next day it saw 49m from a previous 4-5m average leading up to the new year. Financials aren’t incredible. https://www.wsj.com/market-data/quotes/NSPfinancials Chart wise it is in a bullish pattern which is why I’m in it. They need to have some kind of news or PR or something soon on their progress with their products. Thanks again for all of the support. I hope this information is useful :)
Online Gambling Market 2020 Global Industry Reports furnish Detailed Overview Market Growth, size, share, trends, stability Industry policies, Latest innovation, top Manufactures analysis yet ... Apr 21, 2020 (Daily Market Journal via Comtex) -- The report titled "Global Gambling Market: Size, Trends & Forecasts (2020-2024)" provides an in-depth... Global Gambling Market Report 2021: Market to Grow from $465.76 Billion in 2020 to $516.03 Billion in 2021 - Forecast to 2030 Nachricht finanzen.net The global online gambling market was estimated to worth more than €50.85 billion in 2018. Given the huge advances in web technologies and smartphone applications, there has been substantial growth. This includes the gambling industry as a whole in terms of the number of players and hours spent. Trends in the global online gaming market With the closure of casinos in some countries and the ... In recent years, the global gambling market has been developing quite rapidly. The chart below provides data concerning Gross Gambling Yield of the world’s gambling market from 2001 to 2019. GGY is... Online Gambling Market Growth & Trends. The global online gambling market size is expected to reach USD 127.3 billion by 2027, registering a CAGR of 11.5% from 2020 to 2027, according to a new report by Grand View Research, Inc. The market is expected to gain traction over the forecast period. Growing popularity of betting across the globe and freemium model in online gambling are among the ... Online Gambling Market – Global Industry Trends & Forecast . Online Gambling is the primary source of revenue for governments of several countries throughout globally. Moreover, most of the ... The global online gambling market is projected to grow at a CAGR of 11.94%, during the forecast period (2020 - 2025). Online betting is the fastest-growing segment during the forecast period. Artificial intelligence, Chabot, and machine learning have taken over the market. The rise in the number of the female population in casinos and the convenience of the cashless mode of payment during gaming are likely to boost the online gambling market, during the forecast period. The global gambling market is expected to grow from $465.76 billion in 2020 to $516.03 billion in 2021 at a compound annual growth rate (CAGR) of 10.8%. The growth is mainly due to the companies ... The Rise Of Social Gambling/Casino. In 2016, the global social casino market was estimated at $3.81 billion. The social casino market has grown at a CAGR of +23% since 2013. By 2017, the social ...
GLOBAL MARKET TREND WITH NIFTY my secrets#learn with me ...
The traditional input for the processing of vegetables and fruit are seeds. The seed suppliers are interested in supplying fruit and vegetable seeds free of ... The routine procedure of removing excess toxins, solutes, and water from the patient’s blood who is suffering from renal failure or major kidney damage is ca... Which marketing strategies in 2019 should you place your bets on? In this video, Eric Siu shares his marketing predictions for digital marketing trends 2019 ... Fluid control systems are used to regulate body fluid, to avoid risks associated with undesirable amounts of fluid in the human body. To prevent an emergency... Portable medical electronic products are used in the public health care industries to handle, observe and control medical health conditions. They are not con... Veterinary medicines are used to improve the quality of life of animals by treating fungal, parasitic, and viral infections. Veterinary medicines also includ... Power Of Stock market https://www.powerofstocks.com/For Training inquiry call or WhatsApp:- 9739109197.http://partners.fyers.in/AP0231 ,Now op...